References
- Bujko K, Michalski W Kepka L, Nowacki MP Nasierowska-Guttmejer A, Tokar P et al. Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: an analysis of outcomes in a randomized trial. Int J Radiat Oncol Biol Phys 2007; 67: 369-77. 10.1016/j.ijrobp.2006.08.065
- Leibold T, Shia J, Ruo L, Minsky BD, Akhurst T, Gollub M J, et al. Prognostic implications of the distribution of lymph node metastases in rectal cancer after neoadjuvant chemoradiotherapy. J Clin Oncol 2008; 26: 2106-11. 10.1200/JC0.2007.12.770418362367
- Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Lafay I, Hennequin C, Etienne PL, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 2012; 30: 4558-65. 10.1200/JCO.2012.42.877123109696
- Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012; 13: 679-87. 10.1016/S1470-2045(12)70187-022627104
- Velenik V, Ocvirk J, Music, M, Bracko M, Anderluh F, Oblak I, et al. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study. Radiat Oncol. 2011; 6: 105. 10.1186/1748-717X-6-10521880132
- Arbea L, Ramos, LI, Martínez-Monge R, Moreno M, Aristu, J. Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications, Radiat Oncol 2010; 5: 17. 10.1186/1748-717X-5-1720187944
- Guerrero Urbano MT, Henrys AJ, Adams EJ, Norman AR, Bedford JL, Harrington KJ, et al. Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels. Int J Radiat Oncol Biol Phys 2006; 65: 907-16. 10.1016/j.ijrobp.2005.12.05616751073
- Engels B, De Ridder M, Tournel K, Sermeus A, De Coninck P, Verellen D, et al. Preoperative helical tomotherapy and megavoltage computed tomography for rectal cancer: impact on the irradiated volume of small bowel. Int J Radiat Oncol Biol Phys 2009; 74: 1476-80. 10.1016/j.ijrobp.2008.10.01719231097
- Mok H, Crane CH, Palmer MB, Briere TM, Beddar S, Delclos ME, et al. Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma. Radiat Oncol 2011; 6: 63. 10.1186/1748-717X-6-6321651775
- Li JL, Ji JF, Cai Y, Li XF, Li YH, Wu H, et al. Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phase II trial”. Radiother Oncol 2012; 102: 4-9. 10.1016/j.radonc.2011.07.03021903285
- Engels B, Platteaux N, Van den Begin R, Gevaert T, Sermeus A, Storme, G, et al. Preoperative intensity-modulated and image-guided radiotherapy with a simultaneous integrated boost in locally advanced rectal cancer: report on late toxicity and outcome. Radiother Oncol 2014; 110: 155-9. 10.1016/j.radonc.2013.10.02624239243
- Hernando-Requejo O, López M, Cubillo A, Rodriguez A, Ciervide R, Valero J, et al. Complete pathological responses in locally advanced rectal cancer after preoperative IMRT and integrated-boost chemoradiation. Strahlenther Onkol 2014;190: 515-20. 10.1007/s00066-014-0650-024715243
- Picardi V, Macchia G, Guido A, Giaccherini L, Deodato F, Farioli A, et al. Preoperative chemoradiation with VMAT-SIB in rectal cancer: a phase II study. Clin Colorectal Cancer 2016. 10.1016/j.clcc.2016.06.004
- Hong TS, Moughan J, Garofalo MC, Bendell J, Berger AC, Oldenburg NBE, et al. NRG Oncology Radiation Therapy Oncology Group 0822: a phase 2 study of preoperative chemoradiation therapy using intensity modulated radiation therapy in combination with capecitabine and oxaliplatin for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2015; 93: 29-36. 10.1016/j.ijrobp.2015.05.00526163334
- Zhu J, Liu F, Gu W, Lian P, Sheng W, Xu J, et al. “Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study. Radiat Oncol 2014; 9: 70. 10.1186/1748-717X-9-7024606870
- But-Hadzic J, Anderluh F, Brecelj E, Edhemovic I, Secerov-Ermenc A, Hudej R, et al. Acute toxicity and tumor response in locally advanced rectal cancer after preoperative chemoradiation therapy with shortening of the overall treatment time using intensity-modulated radiation therapy with simultaneous integrated boost: a phase 2 trial. Int J Radiat Oncol Biol Phys 2016; 96: 1003-10. 10.1016/j.ijrobp.2016.08.03127727065
- ICRU. Prescribing, recording and reporting photon beam therapy (ICRU report 50). ICRU Report 1993: 357-60. 10.2307/3578862
- Gregoire V, Mackie TR. Dose prescription, reporting and recording in intensity-modulated radiation therapy: a digest of the ICRU Report 83. Imaging Med 2011; 3: 367-73. 10.2217/iim.11.22
- Van Triest B, Nijkamp J, van Herk M, Sonke JJ, de Jong R, Hollmann B, et al. Repeat CT assessed CTV variation and PTV margins for short- and long-course pre-operative RT of rectal cancer. Radiother Oncol 2012; 102: 399-405. 10.1016/j.radonc.2011.11.011
- Glimelius B, Gronberg H, Jarhult J, Wallgren A, Cavallin-Stahl E, Grönberg H, et al. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 2003; 42: 476-92.10.1080/0284186031001230114596508
- U. S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE), Version 4.0 (CTCAE). May 28, 2009: Available at: https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. [Citated 2017 Jun 15].
- Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471–4. 10.1245/s10434-010-0985-420180029
- Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997; 12: 19-23.911214510.1007/s003840050072
- Velenik V, Oblak I, Anderluh F. Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer. Radiat Oncol 2010; 5: 88. 10.1186/1748-717X-5-8820920276
- Burbach JPM, den Harder AM, Intven M, van Vulpen M, Verkooijen HM, Reerink O. Impact of radiotherapy boost on pathological complete response in patients with locally advanced rectal cancer: a systematic review and meta-analysis. Radiother Oncol 2014; 113: 1-9. 10.1016/j.radonc.2014.08.03525281582
- Suwinski R, Taylor JM, Withers HR. Rapid growth of microscopic rectal cancer as a determinant of response to preoperative radiation therapy. Int J Radiat Oncol Biol Phys 1998; 42: 943-51. http://dx.doi.org/10.1016/S0360-3016(98)00343-510.1016/S0360-3016(98)00343-59869214
- Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol 2014; 32: 1554-62. 10.1200/JCO.2013.54.3769
- Brown G, Richards CJ, Bourne MW, Newcombe RG, Radcliffe AG, Dallimore NS, et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology 2003; 227: 371-7. 10.1148/radiol.227201174712732695
- Lobefalo F, Bignardi M, Reggiori G, Tozzi A, Tomatis S, Alongi F, et al. Dosimetric impact of inter-observer variability for 3D conformal radiotherapy and volumetric modulated arc therapy: the rectal tumor target definition case. Radiat Oncol 2013; 8: 176. 10.1186/1748-717X-8-17623837942
- O’Neill BD, Salerno G, Thomas K, Tait DM, Brown G. MR vs CT imaging: low rectal cancer tumour delineation for three-dimensional conformal radiotherapy. Br J Radiol 2009; 82: 509-13. 10.1259/bjr/6019887319153180
- Glynne-Jones R, Mawdsley S, Pearce T, Buyse M. Alternative clinical end points in rectal cancer - are we getting closer? Ann Oncol 2006; 17: 1239-48. 10.1093/annonc/mdl17316873440
- Rödel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23: 8688-96. 10.1200/JCO.2005.02.132916246976